SARS CoV-2 Antibody Persistence During Induction Chemotherapy for Pediatric T-Cell Acute Lymphoblastic Leukemia

J Pediatr Hematol Oncol. 2021 Nov 1;43(8):e1258-e1259. doi: 10.1097/MPH.0000000000002182.

Authors

Janice Pearce¹, Simon Friar², Galina Jigoulina¹, Jessica Bate¹

Affiliations

¹ Department of Paediatric Oncology Southampton Children's Hospital.
² Southampton Specialist Virology Centre University Hospital Southampton NHS Foundation Trust, Southampton, England.

PMID: 33902067
DOI: 10.1097/MPH.0000000000002182

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Viral / blood*
Antibodies, Viral / immunology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
COVID-19 / blood
COVID-19 / immunology*
COVID-19 / virology
Child
Humans
Induction Chemotherapy / methods*
Male
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / blood
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / virology
Prognosis
SARS-CoV-2 / immunology*

Substances

Antibodies, Viral